美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Polaryx Therapeutics, Inc.

8.91

-7.0900-44.31%

盘后：8.47-0.4408-4.95%19:52 EST

成交量：18.88万

成交额：168.37万

市值：4.22亿

市盈率：- -

高：17.20

开：17.20

低：7.35

收：16.00

52周最高：48.91

52周最低：7.35

股本：4,734.33万

流通股本：4,734.33万

量比：6.45

换手率：0.40%

股息：- -

股息率：- -

每股收益(LYR):-0.8876

净资产收益率：--

总资产收益率：--

市净率：79.58

市盈率(LYR):-10.04

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Polaryx Therapeutics, Inc.

交易所：

NASDAQ

成立时间：

2014

员工人数：

11

公司地址：

South Tower,140 E Ridgewood Avenue,Suite 415,Paramus,New Jersey,United States

官网：

http://www.polaryx.com

邮编：

07652

电话：

传真：

- -

简介：

Polaryx Therapeutics, Inc.最初于2014年8月22日在怀俄明州注册成立。2025年10月24日，公司完成了重新注册过程，转为内华达州公司。Polaryx是一家临床阶段的生物技术公司，致力于发现、开发和商业化针对罕见儿童溶酶体储积病（LSDs）的创新疗法。公司采用多模式治疗方法，结合小分子药物疗法和基因疗法，旨在解决这些疾病的遗传原因和下游影响。其领先的药物候选产品PLX-200，针对多种LSDs，并已进入临床试验阶段。Polaryx的药物开发战略以提供安全、有效、以患者为中心的治疗方案为核心，旨在满足这些疾病尚未解决的重大需求。

董事

名称

职位

Alex Yang

Chair of the Board and Chief Executive Officer

Charles Ryan

Independent Director

Francis A. Braun

Independent Director

G. Michael Landis

Chief Financial Officer and Director

Mitchel Berger

Independent Director

股东

名称

职位

Alex Yang

Chair of the Board and Chief Executive Officer

G. Michael Landis

Chief Financial Officer and Director

Andrew O

Chief Investment Officer

Lisa L. Bollinger

Chief Medical Officer

Minsu Kang

Director of Regulatory and Clinical Affairs

Shrijay Vijayan

Chief Scientific and Business Development Officer

Wuxin Zhu

Chief Chemistry, Manufacturing and Controls Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PLYX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics, Inc.","latestPrice":8.91,"timestamp":1770411600000,"preClose":16,"halted":0,"volume":188813,"hourTrading":{"tag":"盘后","latestPrice":8.4692,"preClose":8.91,"latestTime":"19:52 EST","volume":8343,"amount":71693.3642,"timestamp":1770425529825,"change":-0.4408,"changeRate":-0.049473,"amplitude":0.08193},"delay":0,"changeRate":-0.443125,"floatShares":47343297,"shares":47343297,"eps":0,"marketStatus":"已收盘","change":-7.09,"latestTime":"02-06 16:00:00 EST","open":17.2,"high":17.2,"low":7.35,"amount":1683728.59872,"amplitude":0.615625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":16,"preHourTrading":{"tag":"盘前","latestPrice":17,"preClose":16.25,"latestTime":"09:28 EST","volume":393,"amount":6644.939498999999,"timestamp":1770388082496,"change":0.75,"changeRate":0.046154,"amplitude":0.159385},"postHourTrading":{"tag":"盘后","latestPrice":8.4692,"preClose":8.91,"latestTime":"19:52 EST","volume":8343,"amount":71693.3642,"timestamp":1770425529825,"change":-0.4408,"changeRate":-0.049473,"amplitude":0.08193},"volumeRatio":6.4509},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":47343297,"roa":"--","roe":"--","lyrEps":-0.887585,"volumeRatio":6.4509,"shares":47343297,"dividePrice":0,"high":17.2,"amplitude":0.615625,"preClose":16,"low":7.35,"week52Low":7.35,"pbRate":"79.58","week52High":48.91,"institutionHeld":0,"latestPrice":8.91,"eps":0,"divideRate":0,"volume":188813,"delay":0,"ttmEps":0,"open":17.2,"prevYearClose":45,"prevWeekClose":45,"prevMonthClose":45,"prevQuarterClose":45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-02-05","current":-129.699766,"percent":0.25,"low":-201.755192,"twenty":-144.110851,"median":-126.529328,"eighty":-58.797227,"high":-58.797227,"avg":-115.115748,"sd":53.278341,"marketCap":1065224182},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-05","current":-129.699766,"twenty":-144.110851,"median":-126.529328,"eighty":-58.797227,"marketCap":1065224182}],"updateTime":1770426841502},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":414729746,"yearFounded":2014,"employeeNum":11,"address":"South Tower,140 E Ridgewood Avenue,Suite 415,Paramus,New Jersey,United States","zipCode":"07652","officePhone":"201 940 7236"},"stockCompanyDetail":{"websiteUrl":"http://www.polaryx.com","stockEarnings":[{"period":"1week","weight":-0.6444},{"period":"ytd","weight":-0.6444}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Polaryx Therapeutics, Inc.最初于2014年8月22日在怀俄明州注册成立。2025年10月24日，公司完成了重新注册过程，转为内华达州公司。Polaryx是一家临床阶段的生物技术公司，致力于发现、开发和商业化针对罕见儿童溶酶体储积病（LSDs）的创新疗法。公司采用多模式治疗方法，结合小分子药物疗法和基因疗法，旨在解决这些疾病的遗传原因和下游影响。其领先的药物候选产品PLX-200，针对多种LSDs，并已进入临床试验阶段。Polaryx的药物开发战略以提供安全、有效、以患者为中心的治疗方案为核心，旨在满足这些疾病尚未解决的重大需求。","exchange":"NASDAQ","name":"Polaryx Therapeutics, Inc.","nameEN":"Polaryx Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":{"directors":[{"name":"Alex Yang","position":"Chair of the Board and Chief Executive Officer"},{"name":"Charles Ryan","position":"Independent Director"},{"name":"Francis A. Braun","position":"Independent Director"},{"name":"G. Michael Landis","position":"Chief Financial Officer and Director"},{"name":"Mitchel Berger","position":"Independent Director"}],"executives":[{"name":"Alex Yang","position":"Chair of the Board and Chief Executive Officer"},{"name":"G. Michael Landis","position":"Chief Financial Officer and Director"},{"name":"Andrew O","position":"Chief Investment Officer"},{"name":"Lisa L. Bollinger","position":"Chief Medical Officer"},{"name":"Minsu Kang","position":"Director of Regulatory and Clinical Affairs"},{"name":"Shrijay Vijayan","position":"Chief Scientific and Business Development Officer"},{"name":"Wuxin Zhu","position":"Chief Chemistry, Manufacturing and Controls Officer"}]}}}